Cantor Reiterates Buy on Celgene Corporation Ahead of 1Q:15 Update
In a research report issued today, Cantor analyst Mara Goldstein reiterated a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target of $145, ahead of the company’s first-quarter earnings results, which is set to be released on Thursday, April 30. Celgene shares are currently trading at $113.25, down $0.27 or 0.24%.
Goldstein noted, “We expect 1Q:15 EPS of $1.06, in line with FactSet consensus on revenue of $2.1 billion, also in line with consensus. Though the first quarter of the year can present challenges due to timing of discounts and the like, we continue to believe that Celgene has sufficient unit growth to support industry-leading earnings growth. In particular, over the past 20 reporting periods (5 years), we have observed Celgene shares to outperform the biotech market in quarters where the shares trade off after earnings.”
Furthermore, “Celgene shares are trading at roughly 18x 2016E EPS, which may be a higher multiple versus other large cap peers, but not, in our view, relative to growth. And that suggests to us that investors continue to focus on the shares as the likelihood of upward EPS revisions are high, in our view, and growth opportunities are spread throughout the portfolio.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Mara Goldstein has a total average return of 22.3% and a 72.7% success rate. Goldstein has a 34.0% average return when recommending CELG, and is ranked #178 out of 3581 analysts.